CVC  Boehringer Ingelheim Venture Fund

     Office Locations:

One Broadway, 14th Floor
Cambridge, MA 02142

Get all office locations for this firm with a National Database subscription.


  • Early
  • Seed



  • Life Sciences & Healthcare



    The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. The Boehringer Ingelheim Venture Fund's mission is to invest in the development of pioneering science -- from idea to proof of concept -- which offer the potential to provide significant benefits firstly for patients and also for Boehringer Ingelheim's business. Fund has an initial commitment of EURO100 million. Opening investments of up to EURO2 million per venture will be made at the early stage with subsequent staged investments made to align with each venture's progress, up to a total of EURO10-15 million per venture over its life. The Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies that have the potential to advance patient care and meet unmet medical needs.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Frank Kalkbrenner Managing Director
    Ilka Wicke Director, Investment Manager
    Knut Elbers Director, Investment Manager
    Martin Heidecker Director, Investment Manager


    Portfolio companies include:


    Recent News: